VRTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 0.20%

Insider Buying (Last 12 Months): $1,948,400.00

Insider Selling (Last 12 Months): $76,001,618.86

Vertex Pharmaceuticals Insider Trading History Chart

Vertex Pharmaceuticals Share Price & Price History

^$465.61

▼ -6.4 (-1.36%)

As of 02/3/2026 05:00 PM ET

Days: 30 | 90 | 365

Vertex Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/7/2026	Ourania Tatsis	EVP	Sell	4,500	$474.99	$2,137,455.00	42,293
1/6/2026	Charles F. Wagner, Jr.	EVP	Sell	9,532	$461.00	$4,394,252.00	37,725
12/3/2025	Charles F. Wagner, Jr.	EVP	Sell	14,000	$456.00	$6,384,000.00	37,725
12/3/2025	Jeffrey M. Leiden	Chairman	Sell	63,781	$449.20	$28,650,425.20	24,026
11/14/2025	Jeffrey M. Leiden	Chairman	Sell	53,604	$440.72	$23,624,354.88	24,026
11/13/2025	Jeffrey M. Leiden	Chairman	Sell	19,688	$440.27	$8,668,035.76	24,026
8/6/2025	Bruce I. Sachs	Director	Buy	5,000	$389.68	$1,948,400.00	45,000
5/15/2025	David Altshuler	EVP	Sell	52	$424.69	$22,083.88	23,281
3/10/2025	David Altshuler	EVP	Sell	3,231	$500.00	$1,615,500.00	26,512
2/27/2025	Ourania Tatsis	EVP	Sell	530	$475.34	$251,930.20	58,539
2/18/2025	Ourania Tatsis	EVP	Sell	244	$455.06	$111,034.64	67,695
2/11/2025	Ourania Tatsis	EVP	Sell	310	$459.83	$142,547.30	64,021
11/15/2024	David Altshuler	EVP	Sell	15	$478.56	$7,178.40	25,813
8/30/2024	Jeffrey M. Leiden	Chairman	Sell	3,784	$499.00	$1,888,216.00	9,994
8/30/2024	Sangeeta N Bhatia	Director	Sell	646	$500.00	$323,000.00	4,435
8/7/2024	Carmen Bozic	CMO	Sell	2,280	$476.75	$1,086,990.00	23,259
8/1/2024	Bruce I. Sachs	Director	Sell	5,295	$508.00	$2,689,860.00	40,000
7/24/2024	Carmen Bozic	CMO	Sell	2,280	$488.46	$1,113,688.80	25,539
7/22/2024	Reshma Kewalramani	CEO	Sell	15,202	$497.00	$7,555,394.00	106,172
7/10/2024	Carmen Bozic	CMO	Sell	2,280	$487.34	$1,111,135.20	27,819
6/26/2024	Carmen Bozic	CMO	Sell	2,280	$471.72	$1,075,521.60	30,099
6/12/2024	Carmen Bozic	CMO	Sell	2,280	$478.00	$1,089,840.00	32,379
6/12/2024	E. Morrey Atkinson, III	EVP	Sell	7,288	$478.00	$3,483,664.00	15,972
5/30/2024	Ourania Tatsis	EVP	Sell	2,350	$439.11	$1,031,908.50	53,523
5/29/2024	Carmen Bozic	CMO	Sell	2,280	$445.56	$1,015,876.80	34,659
5/28/2024	Charles F. Wagner, Jr.	CFO	Sell	3,250	$454.79	$1,478,067.50	50,387
5/24/2024	Reshma Kewalramani	CEO	Sell	1,565	$457.00	$715,205.00	121,374
5/22/2024	Bruce I. Sachs	Director	Sell	7,073	$448.00	$3,168,704.00	40,000
2/26/2024	Ourania Tatsis	EVP	Sell	354	$425.70	$150,697.80	55,804
2/20/2024	Ourania Tatsis	EVP	Sell	480	$420.79	$201,979.20	59,827
2/12/2024	Amit Sachdev	EVP	Sell	3,222	$420.24	$1,354,013.28	74,364
2/12/2024	Jeffrey M. Leiden	Chairman	Sell	2,656	$419.51	$1,114,218.56	27,644
2/12/2024	Kristen Ambrose	CAO	Sell	1,374	$420.24	$577,409.76	9,676
2/12/2024	Stuart A. Arbuckle	COO	Sell	4,295	$420.24	$1,804,930.80	75,718
1/8/2024	Jeffrey M. Leiden	Chairman	Sell	6,648	$419.07	$2,785,977.36	2,423
11/6/2023	Bruce I. Sachs	Director	Sell	11,250	$385.00	$4,331,250.00	40,000
10/31/2023	Carmen Bozic	CMO	Sell	5,651	$355.92	$2,011,303.92	34,952
10/17/2023	Carmen Bozic	CMO	Sell	5,651	$373.25	$2,109,235.75	40,603
10/17/2023	Sangeeta N Bhatia	Director	Sell	243	$375.00	$91,125.00	3,901
10/16/2023	Jeffrey M. Leiden	Chairman	Sell	12,962	$374.00	$4,847,788.00	22,425
10/6/2023	Sangeeta N Bhatia	Director	Sell	242	$360.00	$87,120.00	4,144
10/3/2023	Carmen Bozic	CMO	Sell	5,651	$345.28	$1,951,177.28	46,254
10/2/2023	Jonathan Biller	EVP	Sell	610	$346.76	$211,523.60	10,569
9/19/2023	Carmen Bozic	CMO	Sell	5,651	$351.00	$1,983,501.00	51,905
8/23/2023	Ourania Tatsis	EVP	Sell	2,500	$355.00	$887,500.00	48,637
8/9/2023	David Altshuler	EVP	Sell	63	$345.51	$21,767.13	32,038
8/9/2023	Sangeeta N Bhatia	Director	Sell	242	$345.51	$83,613.42	4,386
7/17/2023	Bruce I. Sachs	Director	Sell	11,250	$356.75	$4,013,437.50	40,000
7/17/2023	Reshma Kewalramani	CEO	Sell	7,828	$355.00	$2,778,940.00	118,906
6/15/2023	Stuart A. Arbuckle	COO	Sell	8,603	$349.00	$3,002,447.00	56,556
5/30/2023	Kristen Ambrose	CAO	Sell	289	$329.82	$95,317.98	6,838
5/30/2023	Stuart A. Arbuckle	COO	Sell	82	$329.82	$27,045.24	56,556
5/8/2023	Bastiano Sanna	EVP	Sell	2,850	$350.00	$997,500.00	32,038
5/8/2023	Jeffrey M. Leiden	Chairman	Sell	1,125	$349.00	$392,625.00	35,387
5/5/2023	Bastiano Sanna	EVP	Sell	422	$350.03	$147,712.66	34,888
5/5/2023	Jeffrey M. Leiden	Chairman	Sell	879	$349.56	$307,263.24	36,512
5/2/2023	Bastiano Sanna	EVP	Sell	1,622	$350.66	$568,770.52	38,091
5/2/2023	Jeffrey M. Leiden	Chairman	Sell	6,450	$349.89	$2,256,790.50	41,899
5/2/2023	Sangeeta N Bhatia	Director	Sell	580	$348.28	$202,002.40	4,628
4/27/2023	Reshma Kewalramani	CEO	Sell	3,317	$339.08	$1,124,728.36	126,652
4/12/2023	Bastiano Sanna	EVP	Sell	7,567	$326.70	$2,472,138.90	39,713
4/12/2023	Bruce I. Sachs	Director	Sell	21,300	$326.73	$6,959,349.00	41,210
4/4/2023	Bastiano Sanna	EVP	Sell	522	$315.81	$164,852.82	47,280
3/24/2023	Charles F. Wagner, Jr.	CFO	Sell	1,768	$305.38	$539,911.84	49,611
3/17/2023	Charles F. Wagner, Jr.	CFO	Sell	2,000	$296.39	$592,780.00	51,379
3/16/2023	Bastiano Sanna	EVP	Sell	2,746	$300.59	$825,420.14	49,268
3/13/2023	Charles F. Wagner, Jr.	CFO	Sell	2,666	$293.83	$783,350.78	53,379
3/10/2023	Charles F. Wagner, Jr.	CFO	Sell	2,088	$289.61	$604,705.68	56,045
2/27/2023	Kristen Ambrose	CAO	Sell	1,207	$287.55	$347,072.85	7,303
2/27/2023	Ourania Tatsis	EVP	Sell	354	$287.48	$101,767.92	56,805
2/27/2023	Stuart A. Arbuckle	COO	Sell	5,034	$287.47	$1,447,123.98	56,556
2/22/2023	Stuart A. Arbuckle	COO	Sell	2,401	$294.33	$706,686.33	66,304
2/13/2023	Ourania Tatsis	EVP	Sell	275	$298.99	$82,222.25	65,765
2/13/2023	Stuart A. Arbuckle	COO	Sell	4,887	$298.92	$1,460,822.04	82,003
2/6/2023	David Altshuler	EVP	Sell	1,304	$306.00	$399,024.00	68,645

SEC Filings (Institutional Ownership Changes) for Vertex Pharmaceuticals (NASDAQ:VRTX)

90.96% of Vertex Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Vertex Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/3/2026	NewEdge Wealth LLC	8,402	$3.81M	0.0%	+48.8%	0.003%
2/3/2026	Grange Capital LLC	3,279	$1.49M	1.4%	-7.7%	0.001%
2/3/2026	Washington Trust Advisors Inc.	483	$0.22M	0.0%	+38.4%	0.000%
2/3/2026	Drucker Wealth 3.0 LLC	494	$0.22M	0.0%	N/A	0.000%
2/3/2026	F m Investments LLC	9,484	$4.30M	0.2%	-2.9%	0.004%
2/3/2026	Manning & Napier Advisors LLC	427,603	$194.02M	2.5%	-9.9%	0.169%
2/3/2026	Crossmark Global Holdings Inc.	2,797	$1.27M	0.0%	-54.5%	0.001%
2/3/2026	Ethic Inc.	15,983	$7.25M	0.1%	+14.4%	0.006%
2/3/2026	Ballentine Partners LLC	5,290	$2.40M	0.0%	+3.9%	0.002%
2/3/2026	Channel Wealth LLC	6,606	$3M	0.8%	-37.4%	0.003%
2/3/2026	Strengthening Families & Communities LLC	87	$39K	0.0%	+770.0%	0.000%
2/3/2026	Koshinski Asset Management Inc.	1,456	$0.66M	0.0%	+8.7%	0.001%
2/3/2026	International Assets Investment Management LLC	410	$0.19M	0.0%	-17.7%	0.000%
2/3/2026	Diversify Wealth Management LLC	11,690	$5.32M	0.2%	-4.3%	0.005%
2/3/2026	Generali Asset Management SPA SGR	18,538	$8.40M	0.2%	-21.3%	0.007%
2/3/2026	ASR Vermogensbeheer N.V.	26,059	$11.81M	0.1%	-0.9%	0.010%
2/3/2026	MGO One Seven LLC	2,335	$1.06M	0.0%	+8.6%	0.001%
2/3/2026	Crestwood Advisors Group LLC	8,003	$3.63M	0.1%	-12.5%	0.003%
2/3/2026	Bluebird Wealth Management LLC	2,906	$1.32M	1.2%	N/A	0.001%
2/3/2026	Richard Bernstein Advisors LLC	3,367	$1.53M	0.0%	-8.8%	0.001%
2/3/2026	Cabot Wealth Management Inc.	930	$0.42M	0.0%	-41.0%	0.000%
2/3/2026	Retirement Planning Group LLC	470	$0.21M	0.0%	N/A	0.000%
2/3/2026	Sequoia Financial Advisors LLC	13,596	$6.16M	0.0%	-2.7%	0.005%
2/3/2026	Sigma Investment Counselors Inc.	10,021	$4.54M	0.2%	-1.2%	0.004%
2/3/2026	D.B. Root & Company LLC	813	$0.37M	0.1%	-15.0%	0.000%
2/3/2026	Gateway Investment Advisers LLC	66,108	$29.97M	0.3%	+0.3%	0.026%
2/3/2026	Ponta Wealth Partners LLC	479	$0.22M	0.2%	N/A	0.000%
2/3/2026	LaFleur & Godfrey LLC	482	$0.22M	0.0%	N/A	0.000%
2/3/2026	S Bank Fund Management Ltd	1,428	$0.65M	0.1%	-35.2%	0.001%
2/3/2026	RFG Advisory LLC	827	$0.38M	0.0%	N/A	0.000%
2/3/2026	Equitable Trust Co.	496	$0.23M	0.0%	N/A	0.000%
2/3/2026	Swedbank AB	260,743	$118.21M	0.1%	+2.6%	0.103%
2/3/2026	Mitsubishi UFJ Asset Management Co. Ltd.	566,227	$256.01M	0.2%	+3.9%	0.223%
2/3/2026	BOKF NA	5,867	$2.66M	0.0%	-16.6%	0.002%
2/3/2026	Sumitomo Mitsui DS Asset Management Company Ltd	62,761	$28.45M	0.2%	+14.1%	0.025%
2/3/2026	Harel Insurance Investments & Financial Services Ltd.	2,436	$1.10M	0.0%	+18.4%	0.001%
2/3/2026	Privium Fund Management B.V.	9,355	$4.24M	0.8%	+12.7%	0.004%
2/3/2026	SBI Securities Co. Ltd.	1,319	$0.60M	0.0%	-8.8%	0.001%
2/3/2026	Hemenway Trust Co LLC	51,017	$23.13M	1.8%	-7.5%	0.020%
2/3/2026	Tweedy Browne Co LLC	39,148	$17.75M	1.4%	+0.2%	0.015%
2/3/2026	Morse Asset Management Inc	10,423	$4.73M	0.9%	+1.1%	0.004%
2/3/2026	Alta Wealth Advisors LLC	1,625	$0.74M	0.2%	+1.8%	0.001%
2/2/2026	PKS Advisory Services LLC	453	$0.21M	0.0%	N/A	0.000%
2/2/2026	Alliance Wealth Advisors LLC UT	2,344	$1.06M	0.2%	-19.1%	0.001%
2/2/2026	Principal Financial Group Inc.	415,100	$188.19M	0.1%	+2.1%	0.164%
2/2/2026	Fairfield Financial Advisors LTD	1,098	$0.50M	0.2%	+47.8%	0.000%
2/2/2026	QRG Capital Management Inc.	18,396	$8.34M	0.1%	+16.2%	0.007%
2/2/2026	McHugh Group LLC	500	$0.23M	0.1%	N/A	0.000%
2/2/2026	Headinvest LLC	2,307	$1.05M	0.2%	-1.0%	0.001%
2/2/2026	Varma Mutual Pension Insurance Co	40,626	$18.42M	0.1%	+16.3%	0.016%
2/2/2026	Truist Financial Corp	126,193	$57.21M	0.1%	-12.3%	0.050%
2/2/2026	Avidian Wealth Enterprises LLC	1,354	$0.61M	0.0%	+7.7%	0.001%
2/2/2026	Reynders McVeigh Capital Management LLC	53,905	$24.44M	1.1%	-2.6%	0.021%
2/2/2026	Montag A & Associates Inc.	797	$0.36M	0.0%	+279.5%	0.000%
2/2/2026	CENTRAL TRUST Co	7,363	$3.34M	0.1%	-12.3%	0.003%
2/2/2026	PKO Investment Management Joint Stock Co	11,200	$5.08M	0.4%	-2.6%	0.004%
2/2/2026	Souders Financial Advisors	2,006	$0.91M	0.1%	+13.7%	0.001%
2/2/2026	Benjamin Edwards Inc.	11,093	$5.03M	0.1%	+5.7%	0.004%
2/2/2026	Strs Ohio	78,278	$35.49M	0.1%	-2.9%	0.031%
2/2/2026	Sandro Wealth Management LLC	3,167	$1.44M	1.2%	N/A	0.001%
2/2/2026	Ashton Thomas Securities LLC	2,902	$1.32M	0.3%	-2.7%	0.001%
2/2/2026	Composition Wealth LLC	9,834	$4.46M	0.1%	+8.4%	0.004%
2/2/2026	Kornitzer Capital Management Inc. KS	2,245	$1.02M	0.0%	-9.3%	0.001%
2/2/2026	PFA Pension Forsikringsaktieselskab	135,188	$61.34M	0.2%	N/A	0.053%
2/2/2026	Blalock Williams LLC	444	$0.20M	0.2%	N/A	0.000%
2/2/2026	Horizon Investments LLC	11,375	$5.16M	0.1%	+23.7%	0.004%
2/2/2026	Essex Bank	634	$0.29M	0.1%	-11.0%	0.000%
2/2/2026	MN Wealth Advisors LLC	3,150	$1.43M	0.7%	+9.2%	0.001%
2/2/2026	Fifth Third Bancorp	22,158	$10.05M	0.0%	-0.3%	0.009%
2/2/2026	Danske Bank A S	157,165	$71.25M	0.2%	-4.4%	0.062%
2/2/2026	Mutual Advisors LLC	3,476	$1.58M	0.0%	-9.1%	0.001%
2/2/2026	Total Clarity Wealth Management Inc.	1,183	$0.54M	0.1%	-4.0%	0.000%
2/2/2026	Oppenheimer & Co. Inc.	4,272	$1.94M	0.0%	+18.5%	0.002%
2/2/2026	Oppenheimer Asset Management Inc.	16,720	$7.58M	0.1%	-34.3%	0.007%
1/30/2026	Sigma Planning Corp	1,686	$0.76M	0.0%	+3.3%	0.001%
1/30/2026	Cullinan Associates Inc.	51,312	$23.26M	1.6%	-0.2%	0.020%
1/30/2026	Citizens Financial Group Inc. RI	43,403	$19.68M	0.3%	+1.2%	0.017%
1/30/2026	New York State Teachers Retirement System	211,092	$95.70M	0.2%	-0.8%	0.083%
1/30/2026	Jennison Associates LLC	3,249,541	$1.47B	0.9%	-5.9%	1.281%
1/30/2026	Trifecta Capital Advisors LLC	16,497	$7.48M	1.1%	+4.2%	0.007%
1/30/2026	State of New Jersey Common Pension Fund D	87,835	$39.82M	0.1%	-2.5%	0.035%
1/30/2026	Joseph Group Capital Management	10,489	$4.76M	1.2%	+1.2%	0.004%
1/30/2026	US Bancorp DE	29,850	$13.53M	0.0%	-3.3%	0.012%
1/30/2026	W.G. Shaheen & Associates DBA Whitney & Co	44,164	$20.02M	1.6%	+1.4%	0.017%
1/30/2026	GC Wealth Management RIA LLC	1,222	$0.55M	0.0%	-63.3%	0.000%
1/30/2026	Bogart Wealth LLC	27,177	$12.32M	0.5%	+3.9%	0.011%
1/30/2026	Fagan Associates Inc.	26,566	$12.04M	1.6%	+1.0%	0.010%
1/30/2026	Simplicity Wealth LLC	2,418	$1.10M	0.1%	+20.1%	0.001%
1/30/2026	Interchange Capital Partners LLC	620	$0.28M	0.1%	-20.9%	0.000%
1/30/2026	Keybank National Association OH	10,130	$4.59M	0.0%	+0.9%	0.004%
1/30/2026	Covenant Asset Management LLC	11,889	$5.39M	0.6%	-1.8%	0.005%
1/30/2026	Archer Investment Corp	74	$34K	0.0%	+89.7%	0.000%
1/30/2026	Strategic Blueprint LLC	600	$0.27M	0.0%	-66.0%	0.000%
1/30/2026	Oakworth Capital Inc.	114	$52K	0.0%	-48.6%	0.000%
1/30/2026	Wealthfront Advisers LLC	43,169	$19.57M	0.0%	+15.5%	0.017%
1/30/2026	Certuity LLC	6,439	$2.92M	0.1%	+17.1%	0.003%
1/30/2026	Torren Management LLC	77	$35K	0.0%	N/A	0.000%
1/30/2026	Ares Financial Consulting LLC	73	$33K	0.0%	N/A	0.000%
1/30/2026	Mitsubishi UFJ Trust & Banking Corp	162,206	$73.54M	0.2%	+8.2%	0.064%
1/30/2026	M&T Bank Corp	14,732	$6.68M	0.0%	+19.5%	0.006%

Data available starting January 2016

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $465.61

$461.53

$476.83

50 Day Range

MA: $455.45

$425.60

$484.15

52 Week Range

Now: $465.61

$362.50

$519.68

Volume

1,050,703 shs

Average Volume

1,483,824 shs

Market Capitalization

$118.13 billion

P/E Ratio

32.84

Dividend Yield

N/A

Beta

0.3

Who are the company insiders with the largest holdings of Vertex Pharmaceuticals?: Vertex Pharmaceuticals' top insider shareholders include:
Reshma Kewalramani (CEO)
Stuart A Arbuckle (COO)
Amit Sachdev (EVP)
Ourania Tatsis (EVP)
Charles F Wagner Jr (CFO)
Bruce I Sachs (Director)
Charles F Wagner Jr (EVP)
Carmen Bozic (CMO)
Jeffrey M Leiden (Chairman)
David Altshuler (EVP)
Edward Morrow Atkinson III (EVP)
Kristen Ambrose (CAO)
Sangeeta N Bhatia (Director)
Learn More about top insider investors at Vertex Pharmaceuticals.
Who are the major institutional investors of Vertex Pharmaceuticals?: Vertex Pharmaceuticals' top institutional investors include:
Vanguard Group Inc. — 9.50%
Jennison Associates LLC — 1.28%
Assenagon Asset Management S.A. — 0.33%
Pictet Asset Management Holding SA — 0.30%
Sumitomo Mitsui Trust Group Inc. — 0.26%
B. Metzler seel. Sohn & Co. AG — 0.20%
Learn More about top institutional investors of Vertex Pharmaceuticals stock.
Which major investors are selling Vertex Pharmaceuticals stock?: Within the previous quarter, VRTX stock was sold by these institutional investors:
Massachusetts Financial Services Co. MA
Jennison Associates LLC
Congress Asset Management Co.
Vanguard Group Inc.
Aberdeen Group plc
Sumitomo Mitsui Trust Group Inc.
Pictet Asset Management Holding SA
Zurcher Kantonalbank Zurich Cantonalbank
In the last year, company insiders that have sold Vertex Pharmaceuticals company stock include:
Reshma Kewalramani (CEO)
Stuart A Arbuckle (COO)
Amit Sachdev (EVP)
Ourania Tatsis (EVP)
Learn More investors selling Vertex Pharmaceuticals stock.
Which major investors are buying Vertex Pharmaceuticals stock?: During the previous quarter, VRTX stock was acquired by institutional investors including:
B. Metzler seel. Sohn & Co. AG
PFA Pension Forsikringsaktieselskab
Nordea Investment Management AB
Assenagon Asset Management S.A.
OFI Invest Asset Management
IMC Chicago LLC
Mirae Asset Global Investments Co. Ltd.
LBP AM SA